Your browser doesn't support javascript.
loading
The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease.
Shih, Tiffany M; Sail, Kavita R; Jalundhwala, Yash J; Sullivan, Jeffrey; van Eijndhoven, Emma; Zadikoff, Cindy; Marshall, Thomas S; Lakdawalla, Darius N.
Afiliação
  • Shih TM; Precision Health Economics, Los Angeles, CA, USA.
  • Sail KR; AbbVie Inc, North Chicago, IL, USA.
  • Jalundhwala YJ; AbbVie Inc, North Chicago, IL, USA.
  • Sullivan J; Precision Health Economics, Los Angeles, CA, USA.
  • van Eijndhoven E; Precision Health Economics, Los Angeles, CA, USA.
  • Zadikoff C; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Marshall TS; AbbVie Inc, North Chicago, IL, USA.
  • Lakdawalla DN; Precision Health Economics, Los Angeles, CA, USA.
J Med Econ ; 23(3): 297-307, 2020 Mar.
Article em En | MEDLINE | ID: mdl-31779508
Aims: To estimate the relationship between functional status (FS) impairment and nursing home admission (NHA) risk in Parkinson's disease (PD) patients, and quantify the effect of advanced PD (APD) treatment on NHA risk relative to standard of care (SoC).Materials and methods: PD patients were identified in the Medicare Current Beneficiary Survey (MCBS) (1992-2010). A working definition based on the literature and clinical expert input determined APD status. A logit model estimated the relationship between FS impairment and NHA risk. The effect of levodopa-carbidopa intestinal gel (LCIG) on NHA risk relative to SoC was simulated using clinical trial data (control: optimized oral levodopa-carbidopa IR, ClinicalTrials.gov NCT00660387 and NCT0357994).Results: Non-advanced PD and APD significantly increased NHA risk when controlling for demographics (p < 0.01). APD status was no longer significant after controlling for FS limitations, implying that FS limitations explain the increased NHA risk in APD patients. Reduced impairment in FS in patients with APD treated with LCIG reduced risk of NHA by 13.5% relative to SoC.Limitations: This study applies clinical trial results to real-world data. LCIG treatment might have a different effect on NHA risk for the nationally representative population than the effect measured in the trial. Both data sources employ different instruments to measure FS, instrument wording and study follow-up differed, which might bias our estimates. Finally, there lacks consensus on a definition of APD. The prevalence of APD in this study is high, perhaps due to the specific definition used.Conclusions: Patients with APD experience a higher risk in NHA than those with non-advanced disease. This increased risk in NHA in patients with APD is explained by greater limitations in FS. The relative reduction in risk of NHA for the APD population treated with LCIG is quantitatively similar to doubling Medicaid home care services.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Carbidopa / Levodopa / Instituição de Longa Permanência para Idosos / Antiparkinsonianos / Casas de Saúde Tipo de estudo: Clinical_trials / Etiology_studies / Health_economic_evaluation / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Carbidopa / Levodopa / Instituição de Longa Permanência para Idosos / Antiparkinsonianos / Casas de Saúde Tipo de estudo: Clinical_trials / Etiology_studies / Health_economic_evaluation / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article